Abstract:Abstract Background There is an increasing incidence of community-acquired Clostridioides difficile infection (CDI), particularly in IBD. Due to a suspected community outbreak in mid-2023, we aimed to investigate the microbiological and antibiotic resistance profile of CDI in an IBD cohort, employing blind central reading, in order to better understand its epidemiology. Methods This was a prospective study of a University Tertiary Hospital in collaboration with the Infection Control Unit and a central laboratory at the forefront of Infectious Diseases investigation in Portugal (Instituto Ricardo Jorge [IRJ]). Faecal samples from all IBD-related CDI from Apr to Oct 2023, were analysed at IRJ, including isolation and identification of C. difficile strains and testing for antimicrobial susceptibility. Infectious diseases investigators were blinded to patients’ data. Results Eleven patients with IBD (median 42 years, 60.0% female) had at least one episode of CDI, comprising 15 IBD-related CDI cases, which represents 26.3% of all CDI cases in this 6-month period. Moreover, this compares to only 14 cases of IBD-related CDI in the previous four years combined. All patients had UC (66.7% extensive), with a median diagnosis of 11 years. All cases were community-acquired, diagnosed in the context of acute worsening of UC symptoms; 40% required hospitalization. Remarkably, only 2 patients had recent antibiotic therapy, while 3 had a recent visit to the emergency department. No predominant ribotype (RT) was recognised: RT 002/2, RT 017, RT 039, RT 078, RT 106 and RT 839 were identified in similar proportions. There were two new RTs detected, which are under characterization. All isolates were susceptible to vancomycin and metronidazole, but 46.7% were resistant to moxifloxacin, which is higher than ever reported in Portugal. Most cases (n=12) were prescribed vancomycin and followed a taper-and-pulse dosing (n=9). None of the three patients who had a recurrence had received taper-and-pulse dosing. Optimization of UC therapy was performed in all cases, including concomitant immunosuppressive therapy escalation when needed, as recommended. Interestingly, one case, despite having tested positive for C. difficile, had a Clostridioides hathewayi isolated in the culture instead. To our knowledge, this is the first case of C. hathewayi associated diarrhoea resolving upon treatment with vancomycin. Conclusion The absence of a predominant ribotype, excluding a community outbreak, demands heightened CDI vigilance in IBD even in absence of traditional risk factors. Alarming moxifloxacin resistance underscores evolving dynamics. A novel C. hathewayi-associated diarrhoea case and the emergence of two new ribotypes adds complexity.

Clostridioides difficile infection in inflammatory bowel disease: a clinical review

The Elevated Risk of Recurrent Clostridioides Difficile Infection in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis.

The Elevated Risk of Recurrent Clostridioides Difficile Infection in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis

Epidemiological and clinical characteristics of Clostridium difficile infection in patients with refractory inflammatory bowel disease

A Multifaced Aspect of Clostridium difficile Infection in Pediatric Patients with Inflammatory Bowel Disease: Case Series and Literature Review

High Incidence and Morbidity of Clostridium Difficile Infection among Hospitalized Patients with Inflammatory Bowel Disease: A Prospective Observational Cohort Study

Clinical Risk Factors For Clostridium Difficile Infection In A Chinese Tertiary Care Hospital

Inflammatory bowel disease and Clostridium difficile infection: clinical presentation, diagnosis, and management

Molecular Characterization and Antibiotic Resistance of Clostridioides Difficile in Patients with Inflammatory Bowel Disease from Two Hospitals in China

Diagnosis and Management of Clostridioides difficile in Inflammatory Bowel Disease

Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection

Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Clostridioides difficile Infection: A Clinical Review of Pathogenesis, Clinical Considerations, and Treatment Strategies

Risk Factors for Clostridium Difficile Infection in Cirrhotic Patients.

Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease

Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis

Genetic insight into the relationship between inflammatory bowel disease and Clostridioides difficile infection

Disordered Intestinal Microbial Communities During Clostridioides difficile Colonization and Subsequent Infection of Hepatic Cirrhosis Patients in a Tertiary Care Hospital in China

Impacts of Infection with Different Toxigenic Clostridium Difficile Strains on Faecal Microbiota in Children.

S1130 Prevalence and Inpatient Outcomes of Clostridioides difficile Infection in Inflammatory Bowel Disease

P1239 Characterization of Clostridioides strains and antibiotic resistance profile in Inflammatory Bowel Disease patients with Clostridioides infection